Jade Biosciences, Inc. completed a merger with Aerovate Therapeutics on April 28, 2025, resulting in Jade stockholders owning approximately 98.6% of the combined entity, and distributing about $69.6 million in special cash dividends. The merger involved significant financial adjustments including the issuance of about $334.2 million in shares and warrants.